Free Trial

Capricor Therapeutics Q3 2023 Earnings Report

Capricor Therapeutics logo
$13.07 +0.17 (+1.32%)
(As of 12/20/2024 05:40 PM ET)

Capricor Therapeutics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Capricor Therapeutics Revenue Results

Actual Revenue
$6.19 million
Expected Revenue
$3.33 million
Beat/Miss
Beat by +$2.86 million
YoY Revenue Growth
N/A

Capricor Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Capricor Therapeutics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Capricor unlikely impacted by Phan warning letter, says JonesResearch
See More Capricor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capricor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capricor Therapeutics and other key companies, straight to your email.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ:CAPR), Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

View Capricor Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings